Herriot Tabuteau, CEO of Axsome Therapeutics ($AXSM), sold shares on the open market 16 times over the past year, totaling $76.1 million. His most recent sale occurred on February 2, 2026. These sales rank 211th among 11,678 insiders, surpassing the average of $8.6 million per seller and 6.4 transactions. Tabuteau made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 26, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | A | Restricted Stock Units | 54623 | $0.00 | 54,623.0000 | 50,412,640 | 9999.99% | 0.11% |
| Feb. 2, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 32410 | $0.00 | 0.0000 | 50,412,640 | 100.00% | 0.06% |
| Feb. 2, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 32410 | $185.60 | 7,351,729.0000 | 50,412,640 | 0.44% | 0.06% |
| Feb. 2, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 32410 | $8.02 | 7,384,139.0000 | 50,412,640 | 0.44% | 0.06% |
| Jan. 7, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 31261 | $170.38 | 7,351,729.0000 | 50,412,640 | 0.42% | 0.06% |
| Jan. 7, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 31261 | $8.02 | 7,382,990.0000 | 50,412,640 | 0.43% | 0.06% |
| Jan. 6, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 29450 | $172.33 | 7,351,729.0000 | 50,412,640 | 0.40% | 0.06% |
| Jan. 6, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 29450 | $8.02 | 7,381,179.0000 | 50,412,640 | 0.40% | 0.06% |
| Jan. 5, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 78703 | $8.02 | 7,430,432.0000 | 50,412,640 | 1.07% | 0.16% |
| Jan. 5, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 78703 | $171.28 | 7,351,729.0000 | 50,412,640 | 1.06% | 0.16% |
| Jan. 7, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 31261 | $0.00 | 32,410.0000 | 50,412,640 | 49.10% | 0.06% |
| Jan. 6, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 29450 | $0.00 | 63,671.0000 | 50,412,640 | 31.63% | 0.06% |
| Jan. 5, 2026 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 78703 | $0.00 | 93,121.0000 | 50,412,640 | 45.80% | 0.16% |
| Dec. 2, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 49252 | $144.59 | 7,351,729.0000 | 50,412,640 | 0.67% | 0.10% |
| Dec. 4, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 10558 | $0.00 | 171,824.0000 | 50,412,640 | 5.79% | 0.02% |
| Dec. 3, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 20163 | $0.00 | 182,382.0000 | 50,412,640 | 9.95% | 0.04% |
| Dec. 2, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 49252 | $0.00 | 202,545.0000 | 50,412,640 | 19.56% | 0.10% |
| Dec. 4, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 10558 | $148.18 | 7,351,729.0000 | 50,412,640 | 0.14% | 0.02% |
| Dec. 4, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 10558 | $8.02 | 7,362,287.0000 | 50,412,640 | 0.14% | 0.02% |
| Dec. 3, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 20163 | $146.94 | 7,351,729.0000 | 50,412,640 | 0.27% | 0.04% |
| Dec. 3, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 20163 | $8.02 | 7,371,892.0000 | 50,412,640 | 0.27% | 0.04% |
| Dec. 2, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 49252 | $8.02 | 7,400,981.0000 | 50,412,640 | 0.67% | 0.10% |
| Nov. 5, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 21775 | $134.49 | 7,351,729.0000 | 50,412,640 | 0.30% | 0.04% |
| Nov. 3, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 91705 | $8.02 | 7,443,434.0000 | 50,412,640 | 1.25% | 0.18% |
| Nov. 3, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 91705 | $132.34 | 7,351,729.0000 | 50,412,640 | 1.23% | 0.18% |
| Nov. 4, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 50459 | $8.02 | 7,402,188.0000 | 50,412,640 | 0.69% | 0.10% |
| Nov. 4, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 50459 | $133.79 | 7,351,729.0000 | 50,412,640 | 0.68% | 0.10% |
| Nov. 5, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 21775 | $8.02 | 7,373,504.0000 | 50,412,640 | 0.30% | 0.04% |
| Nov. 3, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 91705 | $0.00 | 324,031.0000 | 50,412,640 | 22.06% | 0.18% |
| Nov. 4, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 50459 | $0.00 | 273,572.0000 | 50,412,640 | 15.57% | 0.10% |
| Nov. 5, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 21775 | $0.00 | 251,797.0000 | 50,412,640 | 7.96% | 0.04% |
| Oct. 7, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 13390 | $8.02 | 7,365,119.0000 | 48,765,403 | 0.18% | 0.03% |
| Oct. 6, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 19220 | $120.17 | 7,351,729.0000 | 48,765,403 | 0.26% | 0.04% |
| Oct. 6, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 19220 | $8.02 | 7,370,949.0000 | 48,765,403 | 0.26% | 0.04% |
| Oct. 8, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 12774 | $0.00 | 415,736.0000 | 48,765,403 | 2.98% | 0.03% |
| Oct. 7, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 13390 | $0.00 | 428,510.0000 | 48,765,403 | 3.03% | 0.03% |
| Oct. 6, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 19220 | $0.00 | 441,900.0000 | 48,765,403 | 4.17% | 0.04% |
| Oct. 8, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 12774 | $118.84 | 7,351,729.0000 | 48,765,403 | 0.17% | 0.03% |
| Oct. 8, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 12774 | $8.02 | 7,364,503.0000 | 48,765,403 | 0.17% | 0.03% |
| Oct. 7, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 13390 | $118.77 | 7,351,729.0000 | 48,765,403 | 0.18% | 0.03% |
| Sept. 15, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 15254 | $117.37 | 7,351,729.0000 | 48,765,403 | 0.21% | 0.03% |
| Sept. 12, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 27907 | $8.02 | 7,379,636.0000 | 48,765,403 | 0.38% | 0.06% |
| Sept. 12, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 27907 | $118.96 | 7,351,729.0000 | 48,765,403 | 0.38% | 0.06% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 19719 | $0.00 | 461,120.0000 | 48,765,403 | 4.10% | 0.04% |
| Sept. 15, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 15254 | $0.00 | 480,839.0000 | 48,765,403 | 3.07% | 0.03% |
| Sept. 12, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Stock Option (Right to Buy) | 27907 | $0.00 | 496,093.0000 | 48,765,403 | 5.33% | 0.06% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | S | Common Stock | 19719 | $114.19 | 7,351,729.0000 | 48,765,403 | 0.27% | 0.04% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 19719 | $8.02 | 7,371,448.0000 | 48,765,403 | 0.27% | 0.04% |
| Sept. 15, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | M | Common Stock | 15254 | $8.02 | 7,366,983.0000 | 48,765,403 | 0.21% | 0.03% |
| Feb. 24, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | A | Performance Stock Units | 28609 | $0.00 | 28,609.0000 | 48,765,403 | 9999.99% | 0.06% |
| Feb. 21, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | A | Employee Stock Option (Right to Buy) | 28887 | $0.00 | 28,887.0000 | 48,765,403 | 9999.99% | 0.06% |
| Feb. 21, 2025 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | Chief Executive Officer | A | Restricted Stock Units | 28609 | $0.00 | 28,609.0000 | 48,765,403 | 9999.99% | 0.06% |
| Feb. 27, 2024 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | CHIEF EXECUTIVE OFFICER | A | Restricted Stock Units | 47886 | $0.00 | 47,886.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2024 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | CHIEF EXECUTIVE OFFICER | A | Employee Stock Option (Right to Buy) | 87192 | $0.00 | 87,192.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | CHIEF EXECUTIVE OFFICER | A | Restricted Stock Units | 62400 | $0.00 | 62,400.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Axsome Therapeutics, Inc. | $AXSM | TABUTEAU HERRIOT | CHIEF EXECUTIVE OFFICER | A | Employee Stock Option (Right to Buy) | 110032 | $0.00 | 110,032.0000 | 0 | 9999.99% | 0.00% |